Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation
Clinical trial NCT05761470 · RECRUITING
Trial details
- NCT number
- NCT05761470
- Sponsor
- Ying Lin
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-06
- Primary completion
- 2024-06-30
- Enrollment
- 66
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.